|
|
 |
|
Bausch & Lomb
|
Bausch & Lomb is the eye health company. Its core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products. The Bausch & Lomb name is one of the best known and most respected healthcare brands in the world.
Bausch & Lomb has three product lines: Vision Care, Surgical, and Pharmaceuticals.
Bausch & Lomb's Vision Care business manufactures and markets the world's most comprehensive line of eye care products.
Soft and GP (gas permeable) contact lenses, Lens care products for soft and GP lenses,Eye drops and ointments, magnifiers and eyeglass accessories
Bausch & Lomb develops and markets prescription and over-the-counter drugs used to treat a wide range of eye conditions, including glaucoma, eye allergies, conjunctivitis, and dry eye.
|
|
Please choose the following products of Bausch & Lomb
|
|
|
|
|
Page:1 2 3 4 |
|
|
|
Today's News about Bausch & Lomb |
FTC clears Bausch & Lomb's deal for ISTA Pharma
Antitrust regulators have completed their review of Bausch & Lomb's acquisition of ISTA Pharmaceuticals Inc. and are clearing the deal, the companies said Monday.The companies said the Federal Trade Commission ...
Bausch + Lomb and ISTA Pharmaceuticals Announce Early Termination of Hart-Scott-Rodino Waiting Period
MADISON, NJ and IRVINE, CA-- - Bausch + Lomb, the global eye health company, and ISTA Pharmaceuticals, Inc. , today announced that they received early termination of the required waiting period under the ...
Bausch & Lomb launches $3.48 billion credit
NEW YORK (Reuters) - Bausch and Lomb has set price talk on its $3.48 billion cross-border loan, which was launched today by Citigroup, sources told Thomson Reuters LPC. The loan will refinance the company's existing debt and will also support its acquisition of ISTA Pharmaceuticals . The $2.03 billion covenant-lite U.S. term loan B and $350 million covenant-lite U.S. delayed-draw term loan B are ...
10 Executives Who Lied On Their Resumes - And 2 Who Got Away With It
We learned to day that Yahoo CEO Scott Thompson's resume boasts a computer science degree he never got . This news is likely to have a ripple effect as we learn who else in the Valley has tried to pull a stunt like this. Here's what happened to 10 other executives who fibbed on their resumes. Ronald Zarrella, Bausch & Lomb Title: Chief executive officer Tenure: November 2001 - January 2008 Lie ...
NicOx reports first quarter 2012 financial results
SOPHIA ANTIPOLIS, FRANCE-- -PRESS RELEASE www.nicox.com NicOx S.A. today reports financial results for thefirst three months of 2012 and provides an overview of its activities."NicOx made good progress ...
Bausch+Lomb Seeking Loan
Bausch and Lomb is asking for a nearly 3 and a half billion dollar loan so the comapny can refinance debt and back its acquisition of Ista Pharmaceuticals.
Bausch & Lomb Seeks $3.49 Billion of Loans to Refinance Debt
Bausch & Lomb Inc., the eye-care products maker owned by Warburg Pincus LLC, is seeking $3.485 billion in loans to refinance debt and back its acquisition of Ista Pharmaceuticals Inc. (ISTA) , according to a person with knowledge of the transaction.
Bausch + Lomb seeks $3.5B to make acquisition, refinance debt
B+L said in March that it would acquire Ista Pharmaceuticals for $500 million.
Bausch and Lomb weighs increase of U.S. loan, raises pricing
NEW YORK, May 2 (LPC) - Bausch and Lomb revised pricing on its covenant-lite term loans and is said to be weighing an increase to the size of its US dollar-denominated term loan at the expense of the euro-denominated loan amid ongoing volatility in the European loan market, sources said. "The European market continues to be unsettled so they will have to place more of the debt in U.S. investor ...
ISTA Pharmaceuticals Reports First Quarter 2012 Financial Results
IRVINE, CA-- - ISTA Pharmaceuticals, Inc. , today reported on recent events and financial results for the quarter ended March 31, 2012.Recent EventsOn March 26, 2012, ISTA entered into a definitive merger ...
|
|
